**Table e-4: Genetic features in 17 patients with variants of unknown significance (VUS)** M: men, F: women, y: years

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **ID** | **Sex/age** | **Gene** | **Mutations****cDNA level Protein level** | **Reference** |
| V1 | M/17y | *CAPN3* | c.1986\_1988del/- p.Gly663del/- | **This work** |
| V2 | F/68 y | *CAPN3* | c.755T>G/- p.Met252Arg/- | [1] |
| V3 | F/65 y | *LDB3**DNAJB6* | c.2107G>A/- p.Ala703Thr/-c.116\_118del/- p.Glu41del/- | **This work****This work** |
| V4 | F/24y | *RYR1* | c.10747G>C/- p.Glu3583Gln/- | [2] |
| V5 | M/11 y | *CPT2* | c.614A>G/- p.Tyr205Cys/- | **This work** |
| V6 | M/35 | *DYSF* | c.383G>A/- p.Gly128Glu/- | [3] |
| V7 | F/53 y | *SLC22A5**ANO5* | c.364G>T/c.1535G>A p.Asp122Tyr/p.Arg512Hisc.692G>T/- p.Gly231Val/- | [4]; **This work**[5] |
| V8 | M/74 y | *PLEC* | c.1324G>A/c.92G>A p.Val442Met/p.Arg31Gln | **This work** |
| V9 | M/23 y | *TMEM43**TRAPPC11* | c.413A>G/- p.Gln138Arg/-c.1702C>T/c.2388A>C p.Arg568\*/p.Gly796Gly | **This work****This work** |
| V10 | M/40 y | *CPT2* | c.338C>T p.Ser113Leu | [6] |
| V11 | M/16 y | *ACADS**SEPN1* | c.1231C>T/c.625G>A p.Arg411Trp/p.Gly209Serc.1520A>G/- p.Asn507Ser/- | [7]; [8]**This work** |
| V12 | M/63 y | *ANO5* | c.155A>G/- p.Asn52Ser/- | [9] |
| V13 | M/62 y | *MYH7* | c.3133C>T/- p.Arg1045Cys/- | [10] |
| V14 | M/64 y | *CAPN3* | c.526G>A/- p.Val176Met/- | **This work** |
| V15 | M/22 y | *DYSF* | c.3023G>A/c.3950G>T p.Arg1008Gln/p.Arg1317Leu | **This work** |
| V16 | F/72 y | *RYR1* | c.4999C>T/- p.Arg1667Cys/- | dbSNP entry rs144157950 |
| V17 | M/17 y | *ANO5* | c.1519delT p.Phe507Serfs\*6 | [11] |

**References**

1. Fanin M, Fulizio L, Nascimbeni AC, et al. Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Hum Mutat 2004;24:52-62.
2. Torbergsen T, Karime B, Løseth S. Mutation in the ryanodine receptor (RYR1) gene in a family with slowly progressive axial muscular dystrophy. Neuromuscul Disord 2011;21:694–695.
3. Cacciottolo M, Numitone G, Aurino S, et al. Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations. Eur J Hum Genet 2011;19:974-980.
4. Li FY, El-Hattab AW, Bawle EV, Boles RG, Schmitt ES, Scaglia F, Wong LJ. Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143 subjects evaluated for systemic carnitine deficiency. Hum Mutat 2010;31:E1632-E1651.
5. Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 2010;86:213-221.
6. Taroni F, Verderio E, Dworzak F, Willems PJ, Cavadini P, DiDonato S. Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat Genet1993;4:314-320.
7. Pedersen CB, Kølvraa S, Kølvraa A, et al. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. Hum Genet 2008;124:43-56.
8. Corydon MJ, Gregersen N, Lehnert W, et al. Ethylmalonic aciduria is associated with an amino acid variant of short chain acyl-coenzyme A dehydrogenase. Pediatr Res 1996; 39:1059-1066.
9. Sarkozy A, Deschauer M, Carlier RY, et al. Muscle MRI findings in limb girdle muscular dystrophy type 2L. Neuromuscul Disord 2012;22 Suppl 2:S122-S129.
10. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008;83:630-638.
11. Penttilä S, Palmio J, Suominen T, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology 2012;78:897-903.